In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDLI meeting

This article was originally published in The Gray Sheet

Executive Summary

"Medical Device Update '98" meeting is planned for June 24-25 in Washington, D.C. Among the topics to be addressed by FDAers are: accelerated approvals and reviews (Susan Alpert, director, ODE); quality system regulation (Kimberly Trautman, Good Manufacturing Practices/Quality Systems Expert, Office of Compliance); international harmonization (Larry Kessler, director, Office of Surveillance and Biometrics); postmarket requirements (Thomas Gross, director, Division of Postmarket Surveillance, OSB); and refurbishers (Casper Uldricks, special assistant to the director, OC). For more information call 1/800-956-6293...

You may also be interested in...



3D Carbon Partners With Resolution Medical To Produce More Than 1 Million Nasal Swabs A Week

Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.

ACC 2020: Medtronic’s Evolut TAVR Works In Low-Risk Bicuspid Study

Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.

COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment

The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.

UsernamePublicRestriction

Register

MT010152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel